Enhanced Drug Delivery with Oil‐in‐Water Nanoemulsions: Stability and Sustained Release of Doxorubicin

Author:

Hwang Juyoung12,Park Ji Yeong3,Kang Jio1,Oh Nuri4,Li Chen5,Yoo Chung‐Yul6,Um Wooram3,Kwak Minseok12ORCID

Affiliation:

1. Department of Chemistry and Industry 4.0 Convergence Bionics Engineering Pukyong National University 45 Yongso‐Ro, Nam‐Gu Busan 48513 Republic of Korea

2. Smart Gym‐based Translational Research Center for Active Senior's Healthcare Pukyong National University 45 Yongso‐Ro, Nam‐Gu Busan 48513 Republic of Korea

3. Department of Biotechnology Pukyong National University 45 Yongso‐Ro, Nam‐Gu Busan 48513 Republic of Korea

4. Department of Chemistry and Biology Korea Science Academy of Korea Advanced Institute of Science and Technology 105–47 Baegyanggwanmun‐Ro, Busanjin‐Gu Busan 47162 Republic of Korea

5. School of Materials Science and Engineering Dongguan University of Technology No.1, Daxue Road, Songshan Lake Dongguan Guangdong 523808 P. R. China

6. Department of Energy Systems Research and Chemistry Ajou University Yeongtong‐gu Suwon 16499 Republic of Korea

Abstract

AbstractIn this study, oil‐in‐water nanoemulsions are prepared, an isotropic mixture of oil, surfactant, and cosurfactants. The nanoemulsions exhibit stable structures and are capable of efficiently encapsulating hydrophobic drugs such as doxorubicin (Dox). Compared to polymeric micelles, nanoemulsions demonstrate enhanced stability and loading capacity for Dox. Furthermore, nanoemulsions release Dox steadily over 14 days, with 51.6% released within the initial 24 h and up to 80% over the subsequent period. These properties suggest that nanoemulsions can mitigate the side effects related to the burst release of Dox, thereby improving therapeutic efficacy and safety. Additionally, nanoemulsion‐treated cardiomyocytes show increased viability compared to those treated with free Dox, indicating the potential of nanoemulsions to alleviate Dox‐induced cardiotoxicity. Overall, nanoemulsions hold promise as versatile and efficient drug carriers for improving cancer treatment outcomes.

Funder

National Research Foundation of Korea

Ministry of Science and ICT, South Korea

Ministry of Education

Pukyong National University

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3